La Jolla

MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

Retrieved on: 
Friday, December 10, 2021

The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update was given by Malath Makhay, Ph.D., Director, Scientific Affairs, MediciNova, Inc. during the live poster session.

Key Points: 
  • The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update was given by Malath Makhay, Ph.D., Director, Scientific Affairs, MediciNova, Inc. during the live poster session.
  • In this poster presentation, Dr. Makhay discussed the study objectives, scientific rationale, study design, and demographic and baseline characteristics of the study participants as of August 2021.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids

Retrieved on: 
Tuesday, November 30, 2021

TAAP chemical modification inactivates the active ingredient in Ensysces opioids products including PF614.

Key Points: 
  • TAAP chemical modification inactivates the active ingredient in Ensysces opioids products including PF614.
  • Dr. William Schmidt, Chief Medical Officer of Ensysce, commented: We are encouraged by the results of our trials to date.
  • With our expertise in drug development, we are advancing as expected toward bringing our lead next generation opioids products to market.
  • Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.

Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update

Retrieved on: 
Monday, November 29, 2021

SOLANA BEACH, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fiscal year ended August 31, 2021 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fiscal year ended August 31, 2021 and provided a business update.
  • We achieved significant progress throughout the past year, both clinically and operationally, stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • As of August 31, 2021, the Company had approximately $10,065,408 in cash and marketable securities, compared to $2,142,072 as of August 31, 2020.
  • Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid-signaling pathways, including the endocannabinoid system.

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Monday, November 22, 2021

Dr. Lathia presented efficacy data with MN-166 and PD-1 inhibitor combination therapy in GBM pre-clinical models.

Key Points: 
  • Dr. Lathia presented efficacy data with MN-166 and PD-1 inhibitor combination therapy in GBM pre-clinical models.
  • Models with GBM orthotopic tumors were treated with a PD-1 antibody alone and in combination with MN-166.
  • The addition of MN-166 to PD-1 inhibitor treatment significantly extended survival to a median of 66 days (p
  • Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, GBM is the most common primary malignant brain tumor with a very poor prognosis.

Cend Therapeutics Announces First Patient Dosing in Clinical Trial of CEND-1 for the Treatment of Selected Gastrointestinal Cancers

Retrieved on: 
Tuesday, November 16, 2021

This investigator-initiated clinical trial will combine CEND-1 with FORFIRINOX, a standard chemotherapy regimen for all 3 cancer types.

Key Points: 
  • This investigator-initiated clinical trial will combine CEND-1 with FORFIRINOX, a standard chemotherapy regimen for all 3 cancer types.
  • In colon cancer patients without a K-RAS mutation, the epidermal growth factor receptor (EGFR) therapeutic antibody, panitumumab, will also be given.
  • Cend is a clinical-stage biotech company focused on a novel approach to enable more effective treatments for solid tumor cancers.
  • Cend is also applying its technology to alter immunosuppression selectively within the tumor microenvironment to enable a patients immune system and immunotherapies to more effectively fight cancer.

Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

Retrieved on: 
Monday, November 15, 2021

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the third quarter of 2021 and recent corporate updates.

Key Points: 
  • SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the third quarter of 2021 and recent corporate updates.
  • Federal Grants Funding under federal grants was $1.2 million for the third quarter of 2021 compared to $0.8 million for the third quarter of 2020.
  • G&A Expenses General and administrative expenses were $16.4 million for the third quarter of 2021 compared to $0.3 million for the third quarter of 2020.
  • Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Retrieved on: 
Thursday, November 11, 2021

The amount of TG synthesis in the HepG2 cells was calculated by extracting lipids from the HepG2 cells before and after treatment.

Key Points: 
  • The amount of TG synthesis in the HepG2 cells was calculated by extracting lipids from the HepG2 cells before and after treatment.
  • As a result, it was found that MN-001 had an inhibitory effect on TG synthesis in HepG2 cells.
  • CD36 enhances cellular fatty acid uptake in the liver and is known to be involved in the pathogenesis of fatty liver.
  • CD36 mRNA expression was downregulated in all 4 groups (vehicle, T0901317 alone, AA alone, T0901317 + AA) by adding MN-001.

MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting

Retrieved on: 
Wednesday, November 10, 2021

UM exosomes induce activation of cell signaling pathways and the release of cytokines and growth factors from hepatocytes.

Key Points: 
  • UM exosomes induce activation of cell signaling pathways and the release of cytokines and growth factors from hepatocytes.
  • Dr. Carvajal commented, We are excited about the preclinical data generated with the MIF inhibitor MN-166 in this uveal melanoma model study.
  • Uveal melanoma is the most common primary intraocular malignancy and nearly half of patients ultimately will develop metastasis.
  • In our new study, MN-166 treatment prevented remote metastasis in the orthotopic uveal melanoma model.

Singular Genomics Systems, Inc. Reports Recent Highlights and Third Quarter Financial Results

Retrieved on: 
Tuesday, November 9, 2021

LA JOLLA, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021.

Key Points: 
  • LA JOLLA, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021.
  • Achieved targeted performance specifications at three Early Access Program (EAP) partners labs with the G4 Integrated Solution.
  • Operating expenses for the third quarter of 2021 totaled$17.5 million, compared to$7.8 millionfor the third quarter of 2020.
  • Singular Genomics management team will host a conference call today, November 9, 2021, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Palomar Holdings, Inc. Announces Senior Leadership Update

Retrieved on: 
Monday, November 8, 2021

LA JOLLA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or the “Company”) announced that Jon Christianson, the Company’s Chief Underwriting Officer, will succeed Heath Fisher as President, effective upon Mr. Fisher’s previously announced resignation on April 1, 2022. The Company also announced that Robert Beyerle, Palomar’s Senior Vice President of Inland Marine, will succeed Mr. Christianson as Chief Underwriting Officer, effective upon Mr. Christianson’s appointment as President.

Key Points: 
  • Jon was the third employee at Palomar and like Heath he has been instrumental to our success.
  • I am also pleased to report that Robert Beyerle, our Senior Vice President of Inland Marine, will become our Chief Underwriting Officer.
  • Palomar Holdings, Inc. is the holding company of subsidiaries Palomar Specialty Insurance Company (PSIC), Palomar Specialty Reinsurance Company Bermuda Ltd., Palomar Insurance Agency, Inc. and Palomar Excess and Surplus Insurance Company.
  • Palomars insurance subsidiaries, Palomar Specialty Insurance Company, Palomar Specialty Reinsurance Company Bermuda Ltd., and Palomar Excess and Surplus Insurance Company, have a financial strength rating of A- (Excellent) from A.M. Best.